Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep771 | Nuclear receptors and Signal transduction | ECE2016

The thyroid hormone antagonizes STAT3-dependent transcription in hepatocarcinoma cells

Alonso Merino Elvira , Jose Valino Perez Arturo , Contreras Jurado Constanza , Aranda Ana

The known functions of the thyroid hormones in the liver have expanded from their well-known roles in regulating metabolism to also participate in liver regeneration, senescence and hepatocarcinogenesis. The transcription factors STAT3 and NF-κB play a key role in liver homeostasis, in the response to infection and inflammation and in hepatocarcinoma development. Interleukin 6 (IL-6) and Tumour Necrosis α (TNFα) are the best-known cytokines responsible for hepat...

ea0041ep1072 | Thyroid (non-cancer) | ECE2016

Iodine status and thyroid volume in pregnant women

Dolores Ollero M , Toni Marta , Martinez Juan Pablo , Pineda Jose Javier , Espada Mercedes , Anda Emma

Introduction: Adequate iodine intake is important in pregnant women.Objective: To determinate iodine status and thyroid volumen (TV) in healthy pregnant women from Navarra (Spain), and to evaluate possible influence of diet.Methods: A cross-sectional study of 144 women in the first trimester of pregnancy (single pregnancies) was carried during 2014. We measured thyroid-stimulating hormone (TSH), free thyroxine (fT4) and antithyroid...

ea0041ep1097 | Thyroid cancer | ECE2016

Immunohistochemistry as alternative to DNA sequencing in detection of BRAF V600E mutation in papillary thyroid carcinomas

Paja Miguel , Del Cura Jose L , de Ciriza Maite Perez , Oleaga Amelia , Ugalde Aitziber

Objective: To compare the results of immunohistochemistry (IHC) and DNA sequencing in detection of BRAF V600E mutation in papillary thyroid carcinomas (PTC). BRAF V600E mutation is the most common genetic alteration in papillary thyroid carcinomas and is associated with worse prognosis. Direct sequencing is usually performed, but less expensive immunohistochemistry can be used instead.Methods: Study was performed in 54 consecutive PTCs during 2014–2...

ea0040p15 | (1) | ESEBEC2016

Post-pancreatectomy persistent adult nesidioblastosis: follow-up of 24 years

Almeida Raquel , Santos Ana Paula , Gomes Jose Teixeira , Lima Bastos , Bacelar Conceicao

Introduction: Adult nesidioblastosis is a rare entity that has motivated the publication of several case reports, but long-term outcomes are rarely described. Distal or sub-total pancreatectomy is indicated in cases of severe symptoms or lack of response to medical treatment. We report the case of a patient with persistent nesidioblastosis after pancreatectomy keeping under medical treatment for 24 years.Clinical case: Woman currently with 81-years old, ...

ea0039oc5.10 | Oral Communications 5 | BSPED2015

Pegvisomant treatment for X-linked acrogigantism syndrome

Coxson Edward , Iacovazzo Donato , Bunce Benjamin , Jose Sian , Ellard Sian , Sampson Julian , Korbonits Marta , Burren Christine

Introduction: Chromosome Xq26.3 microduplications have recently been identified, and explained this 11-year-old girl’s marked tall stature. Her severe phenotype illustrates X-linked acrogigantism (X-LAG) and demonstrates therapeutic benefit from growth hormone receptor blockade.Case: A 5.6-year-old girl presented with growth acceleration from 3 years and appearance of secondary dentition, greasy skin and blackheads from age 4. Past medical and famil...

ea0038p7 | Bone | SFEBES2015

Differential effects of parathyroid hormone on key regulators of osteoblast mineralisation

Houston Dean , Myers Katherine , MacRae Vicky , Millan Jose Luis , Staines Katherine , Farquharson Colin

Intermittent PTH therapy is currently the only anabolic therapy for osteoporosis. As the mineralisation of the extracellular matrix of bone is essential for normal function it is vital that the effects of PTH on key regulators of mineralisation are uncovered. Ablation of Alpl, Phospho1 or Smpd3 results in skeletal hypomineralisation and as such this study examined the effects of bovine (b)PTH 1–34 on their expression. MC3T3 (clone-14) osteoblast-like cells display tempora...

ea0038p76 | Clinical practice/governance and case reports | SFEBES2015

Aromatase inhibitor: potential therapy for obesity related hypogonadotropic hypogonadism and gynaecomastia

Myint Khin Swe , Jose Neetha , Gmoez Javier , Ahluwalia Rupa , Venu Maya

Background: Hypogonadotropic hypogonadism (HH) is commonly associated with morbidly obesity. Gynaecomastia is associated feature of hypogonadism and can be deteriorated by testosterone therapy.History: A 49-year-old gentleman with a BMI of 53.2 kg/m2 was referred for management of obesity. He has two children (age 18 and 22). He had obesity associated comorbidities including obstructive sleep apnoea and impaired fasting glucose. He reported le...

ea0038p334 | Pituitary | SFEBES2015

Clinically non-functioning pituitary macroadenomas: presenting features and outcomes: recent experience at a tertiary centre

Yadagiri Mahender , Vijay Arun , Pritchard Mark , Nayak Ananth , Shaw Simon , Saravanappa Natarajan , Ayuk John , Jose Biju

Introduction: Non-functioning pituitary macroadenoma (NFMA) can cause considerable morbidity due to pituitary dysfunction and pressure effects. We present recent experience in managing cases diagnosed with NFMA at a single tertiary centre between January 2009 and October 2013.Results: Of the 63 patients with NFMA, 28 (44%) were females. Age ranged from 22 to 91 (mean 63). Visual disturbance symptoms (35/63; 57%) were the commonest presentation. Headache ...

ea0037ep457 | Diabetes (complications & therapy) | ECE2015

Clinical experience with lixisenatide in patients with obesity and type 2 diabetes

Tejera Cristina , Delgado Esther , Porca Cristina , Morales Francisco , Bellido Diego , Diaz Jose

Introduction: Agonist receptor-GLP1 (AR-GLP1) had demonstrated its utility in obese patients with diabetes type 2. Since August 2013 we have available in Spain a new AR-GLP1 with prandial action in a single daily dose, lixisenatide. There are different clinical trials that support its efficacy and security but the dates from real clinical practice are scarce.Aim: To analyse the efficacy and security in real clinical practice for the treatment of diabetic...

ea0037ep611 | Obesity and cardiovascular endocrinology | ECE2015

C-reactive protein assay in obese paediatric patients: comparison of two laboratory methods

Alves Jose , Manacas Marta , Faria Carolina , Filipe Lia , Silva Susana , Proenca Helena

Introduction: Obesity as a pro-inflammatory state is associated to increased levels of C-reactive protein (CRP). CPR is considered as a cardiovascular (CV) risk independent marker and is being researched as a predictive atherosclerosis biomarker in obese children. The American Heart Association (AHA) recommends a three classes approach when aiming at CV risk stratification (low <1.0 mg/l; moderate 1.0–3.0 mg/l; and high >3.0 mg/l). These classes were extrapolated ...